| Weight change category | Weight change category | Weight change category | Weight change category | Follow-up weight change cohort with SWATH MS data | P-value |
---|---|---|---|---|---|---|
Loss >= 10 kg | Loss >= 3 kg AND < 10 kg | Within 3 kg | Gain >= 3 kg | Cohort | Comparison between 4 categories | |
Number of participants | 4 | 18 | 23 | 38 | 83 | Â |
Number of days of follow-up since Baseline | 391.0 ± 37.0 | 376.3 ± 18.6 | 385.5 ± 29.8 | 388.7 ± 29.8 | 385.2 ± 28.0 | 0.563 |
 Missing | 0 | 0 | 1 | 0 | 1 |  |
Weight change at follow-up since Baseline (kg) | − 20.4 ± 9.8 | − 5.8 ± 2.0 | 0.4 ± 1.6 | 10.9 ± 7.8 | 2.9 ± 10.3 | 1.9e–15 |
 Missing | 0 | 0 | 0 | 0 | 0 |  |
Estimated duration of illness at Baseline (months) | 30.0 ± 26.9 | 13.8 ± 9.3 | 22.7 ± 18.7 | 18.6 ± 18.7 | 19.3 ± 17.4 | 0.595 |
 Missing | 2 | 6 | 5 | 12 | 25 |  |
BeneMin treatment allocation | Â | Â | Â | Â | Â | 0.852 |
 Minocycline | 1 | 8 | 11 | 19 | 39 |  |
 Placebo | 3 | 10 | 12 | 19 | 44 |  |
 Missing | 0 | 0 | 0 | 0 | 0 |  |
Age at baseline (years) | 31.0 ± 5.9 | 27.0 ± 6.1 | 23.9 ± 3.7 | 25.7 ± 5.5 | 25.7 ± 5.4 | 0.099 |
 Missing | 0 | 0 | 0 | 0 | 0 |  |
Gender | Â | Â | Â | Â | Â | 0.543 |
 Female | 1 | 5 | 4 | 13 | 23 |  |
 Male | 3 | 13 | 19 | 25 | 60 |  |
 Missing | 0 | 0 | 0 | 0 | 0 |  |
Weight at baseline (kg) | 110.4 ± 26.2 | 89.8 ± 23.1 | 88.6 ± 25.5 | 83.7 ± 26.0 | 87.7 ± 25.5 | 0.223 |
 Missing | 0 | 0 | 0 | 0 | 0 |  |
BMI at baseline (kg/m2) | 35.0 ± 9.2 | 29.4 ± 7.3 | 28.6 ± 6.9 | 27.6 ± 7.2 | 28.6 ± 7.3 | 0.327 |
 Missing | 0 | 0 | 0 | 0 | 0 |  |
Ethnic origin | Â | Â | Â | Â | Â | 0.176 |
 Asian | 1 | – | 3 | 3 | 7 |  |
 Black | 0 | 2 | 3 | 1 | 6 |  |
 Oriental | 0 | 1 | – | 1 | 2 |  |
 White | 3 | 14 | 11 | 27 | 55 |  |
 Mixed | 0 | – | 2 | – | 2 |  |
 Other | 0 | – | – | – | – |  |
 Missing | 0 | 1 | 4 | 6 | 11 |  |
Education (years) | 13.8 ± 2.5 | 13.4 ± 2.3 | 13.1 ± 1.7 | 12.9 ± 2.1 | 13.1 ± 2.0 | 0.681 |
Missing | 0 | 2 | 3 | 8 | 13 | Â |
Number of participants | 4 | 18 | 23 | 38 | 83 | Â |
Generation of antipsychotic medication at baseline | Â | Â | Â | Â | Â | 0.093 |
 First | 1 | 0 | 0 | 2 | 3 |  |
 Second | 3 | 17 | 23 | 36 | 79 |  |
 First and Second | 0 | 1 | 0 | 0 | 1 |  |
 Missing | 0 | 0 | 0 | 0 | 0 |  |
Generation of antipsychotic medication at follow-up | Â | Â | Â | Â | Â | 0.712 |
 First | 0 | 0 | 0 | 1 | 1 |  |
 Second | 4 | 16 | 22 | 36 | 78 |  |
 First and Second | 0 | 2 | 1 | 1 | 4 |  |
 Missing | 0 | 0 | 0 | 0 | 0 |  |
Baseline PANSS | Â | Â | Â | Â | Â | Â |
 Positive | 20.8 ± 5.3 | 16.1 ± 4.4 | 15.8 ± 5.2 | 16.3 ± 4.8 | 16.3 ± 4.9 | 0.384 |
 Missing | 0 | 0 | 0 | 0 | 0 | 0.966 |
 Negative | 19.0 ± 8.8 | 18.1 ± 6.4 | 16.7 ± 4.1 | 17.7 ± 5.7 | 17.5 ± 5.5 | 0.216 |
 Missing | 0 | 0 | 0 | 0 | 0 | 0.300 |
 General | 41.8 ± 12.3 | 35.3 ± 8.2 | 32.4 ± 5.6 | 32.7 ± 8.6 | 33.6 ± 8.1 |  |
 Missing | 0 | 0 | 0 | 0 | 0 |  |
 Total | 81.5 ± 25.8 | 69.5 ± 14.5 | 64.9 ± 10.5 | 66.7 ± 16.6 | 67.5 ± 15.3 |  |
 Missing | 0 | 0 | 0 | 0 | 0 |  |
Baseline Premorbid IQ (WTAR) | 100.3 ± 12.0 | 101.6 ± 11.5 | 101.9 ± 10.8 | 103.3 ± 10.1 | 102.4 ± 10.5 | 0.909 |
 Missing | 0 | 0 | 0 | 1 | 1 |  |
Baseline Current IQ (short WAIS-III) | 103.3 ± 20.8 | 97.4 ± 14.3 | 95.3 ± 18.2 | 89.6 ± 13.4 | 93.6 ± 15.6 | 0.147 |
 Missing | 0 | 0 | 0 | 0 | 0 |  |
Baseline CDSS | 7.3 ± 6.3 | 6.8 ± 4.9 | 4.5 ± 4.0 | 6.1 ± 4.9 | 5.8 ± 4.7 | 0.419 |
 Missing | 0 | 0 | 0 | 0 | 0 |  |
Baseline GAF | 50.0 ± 14.1 | 54.3 ± 7.6 | 58.6 ± 8.7 | 56.3 ± 10.7 | 56.2 ± 9.8 | 0.305 |
 Missing | 0 | 0 | 0 | 0 | 0 |  |